Diadema Partners’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Diadema Partners’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$290K	Buy	+40,000	New	+$322K	0.05%	121

Other funds holding EPRX

BGC

Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Diadema Partners's EPRX Position: Q1 2026 in Review

Diadema Partners opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q1 2026: 40,000 shares worth $290K. The stake represents 0.05% of the portfolio and ranks #121 among its holdings.

54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

Diadema Partners held 40,000 shares of Eupraxia Pharmaceuticals worth $290K as of Q1 2026.
Eupraxia Pharmaceuticals was a new Diadema Partners position in Q1 2026.
Eupraxia Pharmaceuticals made up 0.05% of Diadema Partners's portfolio in Q1 2026, its #121 holding.
54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.